Plerixafor effectively mobilizes hematopoietic stem cells (HSCs). However, most patients' cells are successfully collected using traditional strategies and there is limited cost-effectiveness data. The objectives of this study were to: (1) summarize the published reports of mobilization using a plerixafor-based strategy during compassionate access programs and (2) describe the Canadian experience with plerixafor during its availability by Health Canada's Special Access Program. A literature search identified reports of plerixafor-based mobilization during compassionate access programs. Overall, successful collection of at least 2 × 10 6 CD34+ cells/ kg was achieved in~75% of patients, and about two-thirds of patients went on to HSCT. A greater proportion of patients had successful collections when plerixafor was used in the upfront or preemptive settings. Plerixafor was made available by Health Canada's SAP from September 2008 to December 2010. In 96 of 132 (73%) patients, there was successful collection of at least 2 × 10 6 CD34+ cells/kg. Ninety-nine (75%) patients went on to receive an autologous transplant. Plerixafor-based mobilization is effective in perceived poor mobilizers. The optimal way to incorporate plerixafor into a mobilization strategy, however, remains to be determined. Centre-specific analysis of resource utilization may help to identify the most cost-effective way to implement various plerixafor-based mobilization strategies.
INTRODUCTION
High-dose chemotherapy followed by autologous hematopoietic SCT (HSCT) is an effective strategy for the treatment of a variety of hematologic malignancies, including multiple myeloma 1,2 and relapsed lymphoma. 3, 4 The collection of an adequate number of HSCs, generally defined as a minimum of 2 × 10 6 CD34+ cells/kg or 5 × 10 6 CD34+ cells/kg for patients with multiple myeloma (MM) who are undergoing a second transplant, is a prerequisite for proceeding to HSCT. Primary mobilization failure occurs in 5-40% of patients. [5] [6] [7] [8] [9] Risk factors for poor mobilization include older age, 10 prior radiation therapy, extensive prior chemotherapy, exposure to lenalidomide or purine analogues and extensive BM involvement by malignancy. [11] [12] [13] Options for those patients who fail to mobilize are limited. For some, they may include BM harvest, which is more invasive, associated with a higher risk of complications and is more resource intensive. Selected patients with a suitable donor may be eligible for allogeneic transplantation, but for many patients, treatment will be limited to salvage or maintenance chemotherapy, which is associated with a high relapse rate. For patients failing an initial mobilization attempt, remobilization failures may be up to 77%. 14 Plerixafor is a bicyclam that reversibly binds to the human CXCR4 receptor, inhibiting interaction with its ligand stromal cell-derived factor-1α. 15, 16 In phase 1 and 2 trials, the use of plerixafor, either alone or in combination with granulocyte colony stimulating factor, significantly increased the number of CD34+ cells collected. 17, 18 Two phase 3, multicentre, randomized, doubleblind, placebo-controlled trials conducted in patients with MM 19 and non-Hodgkin lymphoma 20 undergoing first mobilization demonstrated the superiority of plerixafor plus granulocyte colony stimulating factor over granulocyte colony stimulating factor alone to mobilize a target number of CD34+ cells earlier.
Although upfront use of plerixafor is effective in mobilizing HSCs, there is limited data to support the cost-effectiveness of this approach. This is particularly salient in centres that utilize a combination chemotherapy and granulocyte colony stimulating factor mobilization strategy. The majority of patients do mobilize successfully using more traditional strategies, with plerixaforbased mobilization reserved as a salvage strategy when necessary. More recently, plerixafor has been used preemptively for patients at high risk of mobilization failure based on clinical risk factors, a low pre-collection CD34+ cell count or a suboptimal first-day collection. The choice of mobilization strategy tends to be centreand patient-specific and has been debated and discussed in several recent reviews. 21, 22 Despite this, the practitioner is left with persistent uncertainty.
In Canada, new medications must undergo stringent clinical and economic review via the Common Drug Review Process before formulary listing recommendations are made to publicly funded drug plans. Before Health Canada approval, novel effective therapies may be accessed by Health Canada's Special Access Program (SAP). In the case of plerixafor, the drug cost was absorbed by the manufacturer, Genzyme/Sanofi (Mississauga, ON, Canada), between September 2008 and December 2010, during which time transplant centres were able to use plerixafor in a manner consistent with their preferred practice.
The objectives of this study were to: (1) summarize the published reports of HSC mobilization using a plerixafor-based strategy during compassionate access programs and (2) describe the Canadian experience with plerixafor during its availability by Health Canada's SAP, comparing the Canadian experience to similar identified published reports.
METHODS

Literature review
A literature search was performed to identify published reports of mobilization attempts that have included plerixafor, made available by compassionate access programs. Plerixafor was also available in Europe using Sanofi's Compassionate Use Program from May 2008 to August 2009, and in the US from July 2008 to January 2009. In addition to demographic and prior treatment information, we collected information on how plerixafor was used. This was categorized into three strategies: (1) upfront: plerixafor use was considered to be upfront if it was used as a part of an initial mobilization attempt without regard to the likelihood of mobilization failure; (2) preemptive: use of plerixafor was defined as preemptive if it was added to the mobilization strategy because of an increased likelihood of mobilization failure on the basis of clinical risk factors, low pre-collection CD34+ count, suboptimal first-day collection or other prediction method (s); and (3) salvage. When plerixafor was used as part of the mobilization strategy following a previous failed collection attempt, it was defined as salvage use. The study outcomes that we sought to gather were the proportion of patients who yielded a minimum of 2 × 10 6 CD34+ cells/kg and 5 × 10 6 CD34+ cells/kg and the proportion of patients who ultimately proceeded to HSCT.
Studies published between 1 January 2006 and 18 June 2013 and that met the following inclusion criteria were included: (1) included patients undergoing peripheral blood collection of HSCs for autologous transplantation, (2) measured at least one of our study outcomes described above and (3) prospectively or retrospectively collected data on clinical experience with a plerixafor-based mobilization strategy during a Sanofi's Compassionate Use Program. We excluded unpublished studies and studies published in abstract form only. Two reviewers (DS and JT) independently applied the inclusion and exclusion criteria to the articles identified by the literature search and extracted the data using a standardized data abstraction form.
Canadian experience
Plerixafor was made available by Health Canada's SAP and was funded by Genzyme/Sanofi from September 2008 to December 2010. During this time period, all CBMTG (Canadian Blood and Marrow Transplant Group) transplant centres had access to plerixafor, with the drug cost fully reimbursed by the manufacturer. The drug continued to be made available by the SAP from January 2011 to March 2012 but was no longer provided by Sanofi, so individual centres had to absorb the cost if they were to continue using plerixafor. Following termination of the SAP, CBMTG centres were approached to provide information on their consecutive experience with plerixafor-based mobilization. Data collected included demographic, disease and prior treatment information as well as details of any previous mobilization attempts. Outcome data included the median number of CD34+ cell collection, the proportion of patients from whom a minimum of 2 × 10 6 CD34+ cells/kg and 4 × 10 6 CD34+ cells/kg were collected and the proportion of patients proceeding to transplantation. The Ottawa Hospital Research Ethics Board approved the aggregation of the Canadian data.
RESULTS
Literature review
The literature search yielded 395 articles, 13 of which describing the use of plerixafor during compassionate use programs met our inclusion criteria and were included in the literature review. There were no discrepancies with regard to studies for inclusion between the two reviewers. Study demographics are shown in Table 1 . The median number of study participants was 56 (range 13-580) and the median age was 57 (45-60). Two studies included patients with MM exclusively. 23, 24 In one of these, 24 the objective was to evaluate the safety and efficacy of plerixafor in patients with MM and renal failure. One study included only patients with lymphoma. 25 The other studies included patients with MM and non-Hodgkin lymphoma. Most studies also included small numbers of patients with Hodgkin lymphoma. The median number of prior treatment regimens was reported in 11 articles and ranged between 1 and 3 ( Table 1 ). In all but two papers, at least a proportion of the patients described had undergone a previous mobilization attempt. 26, 27 The mobilization strategies and outcomes are shown in Table 2 . There was one report in which plerixafor was used exclusively in an upfront strategy, 27 one in which plerixafor was used entirely preemptively 26 and three in which it was being used as part of a salvage strategy. [28] [29] [30] In the other studies, a combination of preemptive and salvage strategies were used. In three studies, the strategy was described as being preemptive or salvage, but the specific proportions of each were not provided. 25, 31, 32 All of the articles reported the proportion of patients from whom there was successful collection of at least 2 × 10 6 CD34+ cells/kg with a plerixafor-based strategy. This ranged from 37-100%. Three articles reported the proportion of patients from whom at least 5 × 10 6 CD34+ cells/kg were collected. This was achieved in 22 and 23% of patients in the studies by Hubel et al. 29 and D'Addio et al., 26 respectively. In the Shaughnessy et al. 27 study, 5 × 10 6 CD34+ cells/kg were collected from 81% of patients. The proportion of patients who had proceeded to HSCT at the time Abbreviations: F = female; HL = Hodgkin lymphoma; MM = multiple myeloma; NA = not available; NHL = non-HL.
Plerixafor 28 and ranged from 17 to 87%.
Canadian experience
The Canadian experience with plerixafor-based mobilization during the SAP is summarized in Table 3 . Thirteen CBMTG transplant centres provided data. A total of 132 patients were mobilized using plerixafor, 41 patients with MM and 85 patients with lymphoma. Six patients had other diagnoses, including solid tumours. The median age of the cohort was 58 (19-71) and 44% of the participants were female. Participants had received a median of two (0-7) prior chemotherapy regimens. Most had at least one prior mobilization attempt, median 1 (0-3). In 53 (49%) patients, a cyclophosphamide plus granulocyte colony stimulating factor strategy was used, in 27 (25%) a granulocyte colony stimulating factor only strategy was used and in 18 (16%) a noncyclophosphamide-based chemotherapy plus granulocyte colony stimulating factor strategy was used. In two (2%) patients, stem cell factor was added to granulocyte colony stimulating factor and in nine (8%) patients a strategy other than those described above was used.
In this SAP, Canadian patients received plerixafor as part of a preemptive or salvage mobilization strategy. In no patient was the drug used for upfront mobilization. In 109 (83%) patients, the drug was used as salvage, following a previous failed mobilization attempt. In 23 (17%) patients, the drug was used preemptively on the basis of either clinical risk factors for poor mobilization or a low pre-collection CD34+ cell count. In 96 (73%) patients, there was successful collection of at least 2 × 10 6 CD34+ cells/kg. Of the 23 patients in whom plerixafor was used preemptively, 19 (83%) had successful collections. Of the 109 patients in whom the drug was used as part of a salvage strategy, 77 (71%) had successful collections. In 59 (45%) patients, there was collection of at least 4 × 10 6 CD34+ cells/kg. The median collection yield was 3.8 (0-19.03)x10 6 CD34+ cells/kg. Of the entire cohort, 99 (75%) of patients went on to receive an autologous transplant.
DISCUSSION
Our study summarizes the published experience with plerixaforbased mobilization during compassionate drug access programs and describes the Canadian experience when plerixafor was freely available by Health Canada's SAP. Specifically, it describes the 'real-life' experience of plerixafor use in clinical practice. During these programs, plerixafor was used primarily for patients with MM and lymphoma who had either failed one or more previous mobilization attempts or were predicted to fail based on clinical risk factors. Overall, successful collection of at least 2 × 10 6 CD34+ cells/kg was achieved in~75% of patients and about two-thirds of patients went on to HSCT (however, notably, follow-up was short in many of these studies). Not surprisingly, a greater proportion of patients had successful collections when plerixafor was used in the upfront or preemptive settings. In general, the studies that Abbreviations: HSCT = hematopoietic SCT; NA = not available; P+S = preemptive and salvage strategies used although proportions not stated. Abbreviations: F = female; HSCT = hematopoietic SCT.
Plerixafor-based mobilization: Canadian Sap Experience D Sheppard et al included more heavily pre-treated patients had the lowest numbers of successful collections. The study reporting the poorest proportion of successful collections included patients with the greatest number of prior mobilization attempts. 25 Our data show that Canadian use of plerixafor during the SAP was similar to published reports in that the majority of patients had MM or lymphoma and had failed one or more prior mobilization attempts. Successful collection of a minimum of 2 × 10 6 CD34+ cells/kg was achieved in 73%, the majority of which went on to HSCT. This experience has taught us that Canadian practice was very similar to published experience from the international community.
Without optimal cost-effectiveness data to reflect differences in local practice, use of plerixafor varies widely in terms of (1) patient selection, (2) timing of plerixafor and even the (3) definition of a 'poor mobilizer.' This is also true for Canadian centres and experiences reported in the literature. Interestingly, once plerixafor was no longer freely available by the SAP, its use in Canada decreased significantly. In our centre, certainly its use was restricted to patients who had previously failed mobilization with a traditional strategy. The reasons for this change in clinical practice are not entirely clear. Perhaps, it may simply be a reflection of limited resources, or it may point to a lack of belief in the preemptive use of plerixafor or knowledge of the most costeffective way to incorporate it into an overall mobilization strategy.
How then is plerixafor best used in clinical practice? It is known from randomized trials 19, 20 and clinical experience 27 that plerixafor is effective when used as part of an upfront mobilization strategy. However, as the majority of patients do achieve successful collections with more traditional mobilization approaches, an upfront strategy using plerixafor may not be the most cost effective. Conversely, saving plerixafor until after the patient has failed one or more mobilization attempts is time and resource intensive and may cause unnecessary, and potentially harmful, treatment delays. 22 Recently, the Italian Group for Stem Cell Transplantation sought to define a group of patients, based on clinical risk factors, who were predicted to mobilize poorly. 33 If validated, this tool to identify 'predicted poor mobilizers' could be used to select patients who might benefit from preemptive plerixafor. It may be that a routine upfront strategy is useful in some clinical situations, for example, in MM when the goal is to collect HSCs for multiple courses of high-dose chemotherapy.
Several groups have demonstrated the efficacy and cost effectiveness of preemptive plerixafor use. Li et al. 34 administered plerixafor to patients considered to be at high risk for mobilization failure based on their medical history or a low pre-collection CD34+ cell count. Using this strategy, collection of a minimum of 2 × 10 6 CD34+ cells/kg was achieved in 93% of patients versus 72% of patients mobilized with granulocyte colony stimulating factor alone. Vishnu et al. added plerixafor to granulocyte colony stimulating factor for patients based on suboptimal pre-collection CD34+ counts. Successful collection was achieved in 88% of patients and a decision-analysis model estimated the cost savings to be $19 300 per patient. 35 Other groups have reported similar findings. [36] [37] [38] However, such a strategy requires the presence of a accredited laboratory that can perform timely CD34+ counts to facilitate decision making. Further, as there are only retrospective reports of preemptive plerixafor, and little to guide the timing of its use, there may be centre-to-centre differences with respect to the optimal peripheral blood CD34 'cutoff' before plerixafor is administered. Moreover, issues that surround the apheresis techniques (machine and software, volume of apheresis, apheresis operator) add to this complexity. Despite these issues, for some centres, the pharmacoeconomics of mobilization appear to favour such a dynamic approach. 39 Although mobilization failures have been quoted in the literature to occur in 5-40% of patients, [5] [6] [7] [8] [9] the overall magnitude of the problem is not clear. The risk of failure is affected by many factors, which are patient and centre specific. In addition, the number of CD34+ cells collected is, of course, a surrogate outcome for the outcome of interest, which is the number of patients who proceed to transplantation and achieve long-term successful hematopoietic function. In our literature review the number of patients who went on to HSCT varied widely and no studies reported long-term BM function. One of the strengths of this study is that it provides insight into how plerixafor was used in the absence of such resource constraints. In addition, this is the only report of the Canadian experience with plerixafor. The limitations of this study are that it is retrospective and relied on reporting from Canadian centres. Therefore, it may be subject to bias, misclassification or missing data.
In conclusion, a plerixafor-based mobilization strategy is effective in perceived poor mobilizers. The definition of a poor mobilizer and the optimal way to incorporate plerixafor into a mobilization strategy, however, remain to be determined. Although waiting until a patient has failed one of more mobilization attempts may not be cost effective, the pharmacoeconomics of mobilization likely vary from centre to centre and is affected by multiple factors such as the patient population, infrastructure, available resources and who is paying for plerixafor. Centre-specific analysis of resource utilization may help to identify the most cost-effective way to implement various plerixafor-based mobilization strategies. However, ultimately, a prospective randomized trial comparing current mobilization strategies with robust economic data will be required to resolve the decision-making uncertainties surrounding plerixafor's use.
